Rami Levy's retail empire just launched Good Pharm. A discount pharmacy chain designed to undercut Super-Pharm — Israel's pharmacy monopoly — in the same way his supermarkets undercut Teva and Shufersal.
The pattern is familiar. Levy enters a category where one or two players dominate. He strips out margin. He wins on price and convenience. It works.
Good Pharm launches with the same math: lower cost structure, tighter inventory, direct-to-consumer pricing on OTC and generic pharmaceuticals. Super-Pharm's model depends on regulation and shelf dominance. Levy's depends on volume and speed.
This is structural. Israel's pharmacy sector is about to face the same pressure its grocery and retail sectors faced 15 years ago — when Levy proved that hypermarkets weren't a real moat, just a placeholder until someone built a cheaper one.
Good Pharm will open 50+ locations by end of 2027. Watch the stock prices move.
